IDEMIA/SOPRA-STERIA
3.6.2020 15:45:05 CEST | Business Wire | Press release
The European Union Agency for the Operational Management of Large-Scale IT Systems in the Area of Freedom, Security and Justice (eu-LISA) has awarded a consortium of IDEMIA and Sopra Steria a framework contract for the delivery of a new shared biometric matching system (sBMS). By 2022, the sBMS will be one of the largest biometric systems in the world, integrating a database of over 400 million third-country nationals with their fingerprints and facial images. Based on European biometrics technology, this new system will first serve the identification needs of the new European Entry/Exit System, thus being the cornerstone of the protection of European borders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005529/en/
The contract was awarded following a competitive call for tender (LISA/2019/RP/05 EES BMS and sBMS) by eu-LISA. Its duration is four years, with an option for an extension of up to six years.
The Schengen area, a travel zone where 26 European countries have abolished their internal borders, is key to facilitate the free and unrestricted movement of people. The use of the latest biometric technologies makes it possible to ensure the protection of the external borders in the long term. This shared Biometric Matching System, aiming at fighting against irregular immigration and trans-border crime, will become one of the world’s largest biometric systems when it integrates all the existing and upcoming biometric databases of the European Union.
As a contribution to the Smart Borders initiative and the interoperability framework, the sBMS will not only serve the future Entry/Exit System (EES), but also multiple other systems already in use in the EU, including the Schengen Information System (SIS), the Visa Information System (VIS), Eurodac (European Asylum Dactyloscopy Database) and the future ECRIS-TCN (European Criminal Records Information System for Third Country Nationals).
The companies forming the consortium already support the European Union in the management of other mission-critical large-scale IT systems including VIS, SIS and Eurodac for more than fifteen years. They have experience of working with the national and local administrations of EU Member States and private sector partners to manage the movement of people across air, land and sea borders.
“We thank eu-LISA for their renewed trust. As a contributor to the Smart Borders Initiative from the first discussions with the European Commission, IDEMIA is looking forward to shaping the outcome of this major project, based on our comprehensive understanding of the current European systems. Alongside our partners, we will bring best-in-class biometric technology and our full commitment to contribute to one of the most challenging large-scale biometric databases of the world in terms of accuracy and response time for a safer Europe.” Philippe Barreau, Executive Vice President of IDEMIA in charge of Public Security & Identity.
“As European leader in digital transformation and Homeland Security, Sopra Steria is proud to extend its long-standing partnership with eu-LISA contributing to the implementation of an essential and central piece not only for the future Entry/Exit System but also for the other Core Business Systems. I am convinced that this consortium brings the best solution and service offer to accompany eu-LISA in the achievement of its challenges and to deliver the future shared biometric system with high value for its users.” Laurent Giovachini, Deputy CEO from Sopra Steria.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter.
About Sopra Steria
Sopra Steria, a European leader in consulting, digital services and software development, helps its clients drive their digital transformation to obtain tangible and sustainable benefits. It provides end-to-end solutions to make large companies and organizations more competitive by combining in-depth knowledge of a wide range of business sectors and innovative technologies with a fully collaborative approach. Sopra Steria places people at the heart of everything it does and is committed to making the most of digital technology to build a positive future for its clients. With 46,000 employees in 25 countries, the Group generated revenue of €4.4 billion in 2019.
The world is how we shape it.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005529/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
